Skip to content
OpenCapital
Get started

Kodiak Sciences Inc KOD D&A

D&A at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$123.2M-2.9%
HRO
HarrowHROW
$455K-2.2%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
$121K+3.4%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$1.28M+30.8%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$439K-8.0%
Vera Therapeutics logo
Vera TherapeuticsVERA
$140K+64.7%

Other financials

Income statement

See full
Operating income-$59.8M-1.2%
Net income-$58.2M-1.2%
EPS (diluted)-$0.94+13.8%

Balance sheet

See full
Cash & equivalents$169.5M+22.1%
Total debt$56.0M-17.2%
Total equity$112.1M+3.0%
Total assets$306.0M+2.7%

Cash flow

See full
Operating cash flow-$40.0M-37.6%
CapEx$942.0K+249%
Free cash flow-$41.0M-39.5%

Valuation

See full
Market cap$2.32B+1,477%
Enterprise value$2.2B+2,798%

Returns & leverage

See full
Return on equity-208.8%+2,306pp
Debt / equity0.5×-0.1×
Current ratio3.5×-1.1×

Where this comes from

Reported directly by Kodiak Sciences Inc in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Kodiak Sciences Inc’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kodiak Sciences Inc's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kodiak Sciences Inc's D&A?
Kodiak Sciences Inc (KOD) reported D&A of $4.11M in Q1 2026.
How has Kodiak Sciences Inc's D&A changed year-over-year?
Kodiak Sciences Inc's D&A decreased by 10.7% year-over-year, from $4.6M to $4.11M.
What is the long-term trend for Kodiak Sciences Inc's D&A?
Over 4 years (2021 to 2025), Kodiak Sciences Inc's D&A has grown at a 106.8% compound annual growth rate (CAGR), from $1M to $18.33M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.